Colorectal cancer (CRC) is the third most common malignant tumor in humans. Chemotherapy is used for the treatment of CRC. However, the effect of chemotherapy remains unsatisfactory due to drug resistance. Growing evidence has shown that the presence of highly metastatic tumor stem cells, regulation of non-coding RNAs and the tumor microenvironment contributes to drug resistance mechanisms in CRC. Wnt/β-catenin signaling mediates the chemoresistance of CRC in these three aspects. Therefore, the present study analyzed the abundant evidence of the contribution of Wnt/β-catenin signaling to the development of drug resistance in CRC and discussed its possible role in improving the chemosensitivity of CRC, which may provide guidelines for its clinical treatment.
Globally, colorectal cancer (CRC) is the third most commonly diagnosed malignant tumor and is the second leading cause of cancer-associated mortality (1). Overall, the incidence rate and mortality rate of CRC are rising rapidly in several low-income and middle-income countries (2). Although the mortality rate of CRC tends to be stable or declining in developed countries, it is still higher than that in low-income and middle-income countries (2). By 2030, the global CRC burden is expected to increase by 60%, reaching >2.2 million new cases and 1.1 million mortalities (3). The majority of newly-diagnosed CRC cases are classified as a sporadic form (4), and the occurrence and development of CRC is a long-term process. Conventional CRC begins with changes in the cell morphology of the colonic epithelium, which proliferates uncontrollably to form benign polyps. Gradually, it develops into a highly atypical hyperplastic advanced adenoma, which causes a loss of epithelial structure and function to form an invasive tumor (5,6).
A number of factors contribute to the formation of CRC. Genetic susceptibility is a major driver of early CRC occurrence. A study has demonstrated that CRC contains ≤80 mutations, of which <15 mutations are the driving force for tumorigenesis (7). The probability of developing CRC is also associated with personal features and habits, such as age, gender, race/ethnicity, chronic disease history, dietary factors, obesity, low physical activity, smoking and intestinal microflora (4,8,9). Chemotherapy based on 5-fluorouracil (5-FU) has been the main treatment method for patients with CRC since the 1950s (10–12). More chemotherapeutic drugs, such as oxaliplatin (L-OHP), irinotecan and capecitabine, have been developed in recent years and the emergence of monoclonal antibodies, such as bevacizumab and cetuximab, have greatly advanced chemotherapy for CRC (13). However, even if the current response rate to various systemic chemotherapy regimens reaches 50%, most patients develop resistance within 3–12 months (14,15). Drug resistance refers to the gradual decline in the response to drugs during the treatment of various diseases (16). Resistance to chemotherapy drugs is a major limitation in the use of chemotherapy (17). The failure of chemotherapy due to cancer progression and resistance underlies the majority of cancer-associated deaths (18). Therefore, it is necessary to explore drug resistance mechanisms and reversal strategies of CRC chemotherapy.
Previous studies have demonstrated that tumor stem cells (CSCs), non-coding RNAs (ncRNAs) and disordered tumor microenvironment (TME) contribute to the resistance of CRC (19–22). Notably, Wnt/β-catenin signaling has been reported to regulate the formation of CRC via these three aspects (23,24). It is hypothesized that the dysregulation of the Wnt/β-catenin signaling is related to chemotherapy resistance in CRC. At present, numerous studies have sustained this view (25–27), but there is no systematic summary to the best of our knowledge. Therefore, the present authors have systematically reviewed the reported studies on Wnt/β-catenin signaling-mediated chemotherapy resistance of CRC, which may provide clinical reference for the future.
Method
Studies were retrieved from the Pubmed (https://pubmed.ncbi.nlm.nih.gov/) and Web of Science databases (https://www.webofknowledge.com) using ‘Wnt’, ‘β-catenin’, ‘CRC’, ‘drug resistance’ and ‘multidrug resistance’ (MDR) as key words. The retrieved literature ranged from 1980 to the present and the last search was performed on August 28, 2020. The present review focuses on the role of Wnt/β-catenin signaling in CRC resistance and the inhibition of Wnt/β-catenin signaling to study the regulation of CRC resistance.
Wnt/β-catenin signaling pathway
The Wnt gene was first identified in mouse mammary tumors in 1982 and was originally named the int1 gene (28). Subsequent investigation showed that the int gene serves an important role in embryo growth and development in mice, and its function is similar to the Drosophila wingless gene (29). The int1 gene and wingless gene are collectively referred to as the Wnt gene (29). The Wnt signaling pathway is one of the key signaling pathways in the regulation of cell proliferation and it serves a significant role in the pathological process of malignant tumors (30–34). The Wnt gene is composed of various glycoproteins, is a member of the coiled family of transmembrane receptors and is the coreceptor for lipoprotein receptor-related protein (LRP) family and other downstream components (35). There are currently 19 Wnt ligands in mammals that function via autocrine and paracrine pathways (36,37). These various Wnt ligands serve different roles in the development of organisms and the aberrant expression of Wnt ligand genes can lead to the occurrence and development of different types of tumors (Table I) (78). Wnt ligands are divided into two classes according to the different binding methods with downstream receptors. One group binds to the Frizzled (Fzd) and low-density lipoprotein-related receptor 5/6 (LRP/6) to activate canonical β-catenin-dependent pathways. The other group binds Fzd protein to activate the cyclic guanosine monophosphate protein and the noncanonical Wnt pathway (79). β-catenin is the central molecule in the canonical Wnt pathway that controls the switch of the Wnt signaling pathway. Therefore, it is also called Wnt/β-catenin signaling (80). Wnt ligands do not bind to the receptor in normal mature cells, and Wnt/β-catenin signaling is in an ‘off’ state (81). Adenomatous polyposis coli (APC) protein, framework protein Axin, glycogen synthase kinase 3β (GSK3β) and casein kinase 1 (CK1) form a complex that causes degradation of β-catenin (82). This complex degrades β-catenin, which is phosphorylated, modified by ubiquitin and ultimately degraded by the proteasome (83). Eventually, the concentration of β-catenin is decreased, nuclear translocation is suppressed, and downstream target genes, including c-Myc, cyclin D1, survivin and porous metalloproteinase, cannot be activated (83). When Wnt ligands bind to transmembrane Fzd receptors and LRP5/6, CK1 and GSK3β are attracted to LRP5/6 and function as phosphorylases of LRP5/6, which prevents formation of the protein complexes that degrade β-catenin (84). Continuously increasing concentrations of free β-catenin enter the nucleus via the nuclear pore membrane and bind to transcription factor/lymphocyte-enhancing factor (TCF/LEF) (85). Binding promotes the transcription of downstream target genes that affect cell proliferation, apoptosis, stromal lysis and angiogenesis (85). Wnt ligands bind to the receptor, and Wnt/β-catenin signaling is in an ‘on’ state (81). The details are shown in Fig. 1.
Wnt/β-catenin signaling in CRC drug resistance
The resistance of human tumors to anticancer drugs is primarily due to the inherent chemical resistance of tumor cells, generally attributed to gene mutation, gene amplification or epigenetic changes, which affect absorption, metabolism or the export of drugs by a single cell (19). CRC cells exhibit varied resistance to different chemotherapy drugs, including 5-FU, L-OHP and irinotecan, depending on enhanced intracellular metabolism, upregulation or changes in intracellular targets, increased dihydropyrimidine dehydrogenase and thymidine synthase activities, upregulated levels of the diminished form glutathione or increased nucleotide excision repair (86,87). Resistance to capecitabine is accomplished via methylation of the gene encoding thymidine phosphorylase and inactivation of capecitabine (88). For the checkpoint inhibitors, including ipilimumab, pembrolizumab and nivolumab, tumors primarily achieve resistance via tumor mutation and adaptation, decreased production or expression of neoantigens, overexpression of indoleamine 2,3-dioxygenase and decreased expression of phosphatase and tensin homolog (PTEN) (89). Ghadimi et al (90) reported that the Wnt transcription factor TCF7L2 is overexpressed in 5-FU-resistant primary rectal cancer. The stimulation of Wnt3a leads to the strong activation of Wnt/β-catenin signaling in SW480, SW837 and LS1034 CRC cells (91). At the same time, the activity of TCF/LEF reporter gene is rapidly increased, which results in resistance to 5-FU (91). The inhibition of β-catenin can avoid the therapeutic resistance caused by enhanced TCF/LEF gene activity (91). Another study also demonstrated that the sensitivity of CRC cells to 5-FU can be adjusted through Wnt/β-catenin signaling pathway (92). In addition, pharmacological or genetic inhibition of β-catenin can change the chemical sensitivity of SW480 and SW620 CRC cells to 5-FU and L-OHP by regulating the Wnt/β-catenin-Jagged 2-p21 axis (93). Silencing of the T cell factor 4 (Tcf4) gene, which is a downstream effector of Wnt/β-catenin signaling, sensitizes SW1874, SW1396, SW480 and SW-Sc CRC to L-OHP. This sensitization effect may be due to different mechanisms, including the Tcf4 motif in the ATP-binding cassette subfamily B member 1 (ABCB1) promoter, defects in the nucleotide excision repair or double strand break repair system after Tcf4-silencing (87). Wnt inhibitors also improve chemosensitivity (94,95). Among these inhibitors, 4-acetylantroquinol B, which is isolated from the mycelia of Ganoderma camphora, negatively regulates the stem cell maintenance signaling transduction pathway LGR5/Wnt/β-catenin and is most effective in reducing stem-related chemical resistance (96). The present study mainly reviewed the molecular mechanisms of Wnt/β-catenin signaling through CSCs, ncRNAs and TME that mediate the chemotherapy resistance of CRC.
Wnt/β-catenin signaling and CSCs
CSCs are cells that promote the development of tumors, and have the ability to self-renew and have multiple differentiation potentials (97,98). CSCs have four known characteristics, including self-renewal, differentiation, tumorigenic and specific surface markers. These cells are responsible for tumor occurrence, development, metastasis, recurrence and drug resistance (20,99). CSCs are naturally chemoresistant. CSCs are functionally protected in the tissue stem cell niche during chemotherapy (100). The CSCs niche is mainly composed of fibroblasts and endothelial, mesenchymal and immune cells (101,102). These adjacent cells promote the molecular signaling pathways required for the maintenance and survival of CSCs and trigger the endogenous drug resistance of CSCs (103). In addition, the extracellular matrix of niches can protect CSCs from the invasion of therapeutic drugs (100).
Wnt/β-catenin signaling is a necessary pathway for the initial activation, self-renewal and cloning ability of CSCs (104). Fevr et al (105) reported that tissue-specific and inducible β-catenin gene ablation blocks Wnt/β-catenin signaling and reduces the proliferation ability of CSCs. Wnt/β-catenin signaling regulates the expression of surface markers of CSCs (106,107). Leucine-rich repeat-containing G-protein-coupled receptor 5 (LGR5) is a target gene of the Wnt pathway and a marker of CSCs (107). Activation of Wnt/β-catenin signaling increases the level of the CSC cell surface marker LGR5 in the CRC cell lines HCT116, SW480 and DLD1 and enriches gene signatures associated with stemness and cancer relapse in CSCs (108). LGR5-positive CSCs are chemotherapy-resistant (109). The rapid proliferation of CSCs may transform LGR5-negative cells into LGR5-positive cells, which makes the cells enter a static state to escape the toxicity of drugs (110). However, CSCs of the CRC cell lines LoVo, HT29 and HCT116 also obtain drug resistance via the upregulation of drug-resistant drug pumps mediated by LGR5 (107). As CSCs and normal stem cells have very similar characteristics, most of these cells are in the G0 phase of the cell cycle and express specific ATP-binding cassette proteins (ABC transporter) (111). The ABC transporter is a drug pump that mediates the outflow or uptake of a specific substrate. This mechanism takes place at cell membranes (including plasma membrane, endoplasmic reticulum, Golgi body, peroxisome and mitochondria) (112). ABC transporters expel numerous types of drugs from cancer cells and induce chemical resistance in numerous solid tumors (113,114). ABCB1 was the first cloned human ABC transporter (115). A study has shown that ABC inhibitors can inhibit ABC transporters with high potency and specificity and do not adversely affect the pharmacokinetics of therapeutic drugs that can kill cancer cells (116). NSC239225, as one of the ABC transporter inhibitors, can inhibit ABCB1 to increase the sensitivity of SW480TR CRC cells to some drugs, such as paclitaxel (PTX), doxorubicin and mitoxantrone. Its inhibitory effect is mainly achieved through stimulating ATP hydrolysis and directly binding to the iodoarylazidoprazosin (IAAP)-specific substrate binding site (117). Parguerenes I and II, which also act as ABC transporter inhibitors, can repress ABCB1 by modifying the extracellular substrate binding site of ABCB1, thereby reducing the resistance of SW620 and SW620 Ad300 CRC cells to PTX, Doxorubicin and vincristine (118). Studies have shown that Wnt/β-catenin signaling is closely related to the ABC transporter of CSCs (25,119). Inhibition of Wnt/β-catenin signaling downregulates the expression of mRNA related to the ABC transporter, which makes SW480 CRC cells more sensitive to PTX and irinotecan (25). The ABCB1 level of SW620/AD CRC cells is also positively correlated with Wnt/β-catenin signaling transduction activity (120). Notably, Kugimiya et al (121) demonstrated that the downstream target gene of the Wnt/β-catenin signaling, c-Myc, makes COLO-320 CRC cells resistant to the chemical 5-FU by regulating the expression of ABCB5. This effect is primarily achieved by c-Myc-mediated regulation of the ABC transporter gene expression via binding to the upstream promoter (121). Wang et al (122) demonstrated that the transient receptor potential channel short transient receptor potential channel 5 (TRPC5)-induces an increase in [Ca2+], promoting the transport of β-catenin to the nucleus, which serves an important role in ABCB1-induced resistance to 5-FU in CRC cells. Inhibition of TRPC5 using TRPC5-specific siRNA further inhibits the Wnt/β-catenin signaling pathway, reduces the induction of ABCB1 and reverses the resistance of HCT-8 and LoVo CRC cells to 5-FU (122).
Increased glycolysis is also an important cause of CSC drug resistance. The stem cell niche is an anoxic functional chamber that induces CSCs to reprogram for glycolysis (123). This effect promotes the expression of genes involved in apoptosis resistance, which enables the cells to survive in a hostile environment and avoid the influence of chemotherapy (123). Abnormal activation of Wnt/β-catenin signaling transduction is observed in a number of types of human cancer, which promotes glycolysis via the upregulation of solute carrier family 2, facilitated glucose transporter member 1 expression through its target gene c-Myc (124). The role of Wnt/β-catenin signaling transduction in promoting glycolysis is related to drug resistance (125)
Wnt/β-catenin signaling and ncRNAs
Unlike mRNA, ncRNAs lack the potential to encode proteins or peptides (126). ncRNAs are divided into microRNAs (miRNAs/miR) (20–24 nt) (127), long non-coding RNAs (lncRNA) (>200 nt) (128), extracellular RNAs (129), circular RNAs (crcRNA) (130) (100–10,000 nt) and intronic RNAs (131). Previous studies have demonstrated that lncRNAs and miRNA affect the chemotherapy sensitivity of CRC cells via regulation of the Wnt/β-catenin signaling pathway (Table II) (26,131,132). miRNAs regulate Wnt/β-catenin signaling by targeting Wnt ligands (133). Wnt10b is the downstream target of miR-148a, and miR-148a-overexpression inhibits Wnt10b expression and Wnt/β-catenin signaling activity, enhancing cisplatin resistance in SW480 CRC cells (26). Another study demonstrated that miR-103/107 prevents the ormation of the β-catenin complex by repressing Axis inhibition protein 2, which prolongs the duration of Wnt/β-catenin signaling and leads to the continuous induction of Wnt-responsive genes (131). Persistent effects of Wnt/β-catenin signaling stimulates multiple stem-like features in HCT116 and HT29 CRC cells, including chemical resistance (131). GSK3β is also an important component of the β-catenin complex. Inhibition of miR-224 upregulates GSK3β expression in Wnt/β-catenin signaling (134). Therefore, Wnt/β-catenin signaling activity and survivin (an apoptosis inhibitory gene) expression are inhibited, which reduces the adriamycin resistance of CRC SW480 cells (134,135). miR-506 also reverses the downstream target genes of MDR protein 1 (MDR1)/permeability-glycoprotein (P-gp)-mediated L-OHP resistance via inhibition of Wnt/β-catenin signaling (132). Wnt/β-catenin signaling also acts on some miRNAs to regulate the resistance to CRC (136–138). The P53 gene is a well-known tumor suppressor gene (136). Extensive research has reported that mutant p53 not only serves a key role in the transformation process of CRC, but also contributes to the invasiveness of CRC (137,138). Since the discovery of the P53 gene, the regulation of the p53 pathway has aroused interest (139). There is a negative regulatory relationship between wild-type P53 and MDR1, which enhances tumor cell sensitivity to 5-FU (140). Patients with mutant p53 genes are generally resistant to CRC therapies and have a poor prognosis (141). Kwak et al (142) reported that the ectopic expression of miR-552 enhances the resistance to drug-induced apoptosis and that miR-522 directly targets p53. Further genetic and pharmacological experiments showed that the Wnt/β-catenin signaling pathway and its main downstream target, c-Myc, increase the level of miR-552 (142). Therefore, Wnt regulates tumor suppressor genes via miRNAs, which leads to drug resistance. Wnt/β-catenin signaling also transactivates miR-372/373 (143). Overexpression of miR-372/373 enhances the stemness of CRC cells by enriching CD26/CD24, which promotes self-renewal, chemotherapy resistance and the invasion of CRC cells (144).
lncRNAs also affect the chemosensitivity of CRC by regulating the Wnt/β-catenin signaling (145–157). Han et al (145) used reverse transcription-quantitative PCR and functional testing of CRC tissues and cell lines and identified that lncRNA CRNDE activates the downstream targets β-catenin and TCF4 via binding to miR-181a-5p, which causes resistance to 5-FU and L-OHP. Xiao et al (146) demonstrated that lncRNA HOTAIR knockout and mir-203a-3p overexpression inhibited the Wnt/β-catenin signaling pathway, thereby inhibiting cell proliferation and reducing chemoresistance. Another study confirmed that lncRNA H19 increases proliferation via activation of the Wnt/β-catenin signaling, which promotes the resistance of HT-29 CRC to methotrexate (147). CRC-related lncRNA CCAL is another key regulator of CRC progression. Clinical data has demonstrated that patients with CRC with high CCAL expression have shorter overall survival rates, and promotes the resistance of CRC cells to L-OHP (148). A subsequent study showed that the CCAL promoter region possesses reduced methylation and increased acetylation in patients with CRC, which promotes its expression. Upregulated CCAL activates Wnt/β-catenin signaling via inhibition of activating enhancer-binding protein 2α, which upregulates MDR1P-gp and induces MDR (149).
Wnt/β-catenin signaling and TME
Previous studies of chemical resistance primarily focused on the tumor cells themselves, but TME has also received attention (150,151). Various cytokines secreted in the tumor microenvironment, including those from cancer-associated fibroblasts (CAFs), immune cells, inflammatory factors and chemokines, may interact with Wnt/β-catenin signaling to cause a heterogeneous distribution of β-catenin in cells (152–154). Clear colocalization between CAFs and tumor cells expressing nuclear β-catenin is observed in primary CRC samples (27). These findings indicate a close relationship between drug resistance and the tumor environment, especially CAFs (27). A study has demonstrated that exosomes are ideal carriers for the delivery of insoluble hydrophobic Wnt proteins (155). CAF-derived exosomes contribute to the secretion of Wnt ligands, promote the phenotypic recovery of differentiated CRC cells and the function of CSCs characteristics by carrying Wnt ligands. These ligands activate Wnt/β-catenin signaling to regulate Wnt activity (27). All of these actions contribute to drug resistance (Fig. 2). Hu et al (156) treated human SW480, SW620 and LoVo CRC cells with CAF-conditioned medium (CAFs-CM). The results showed that CAF secretes exosomes into CRC cells, which leads to a significant increase in miR-92a-3p levels in CRC cells. The increased expression of miR-92a-3p activates the Wnt/β-catenin pathway and inhibits mitochondrial apoptosis via direct inhibition of the tumor suppressor gene F-box/WD repeat-containing protein 7 and apoptosis regulator 1, which promotes the resistance of CRC cells to 5-FU/L-OHP (157). Similarly, periodin secreted by fibroblasts also activates Wnt/β-catenin signaling, which promotes differentiated CRC cells to restore CSCs characteristics and functions (158). DNA damage caused by chemotherapy promotes CAFs to produce numerous soluble factors, including Wnt16B and stable free radical polymerization 2 (SFRP2) (159). Wnt16B promotes tumor growth via activation of the canonical pathway in cancer cells, which reduces treatment sensitivity (159). SFRP2 acts as a synergistic effector that further enhances the drug resistance of Wnt16B/β-catenin (160). SFRP2 also participates in the non-canonical pathway, including angiogenesis, via activation of calcineurin/nuclear factor of activated T cells, cytoplasmic 3 signaling in endothelial cells, which indirectly promotes tumor development (Fig. 3) (160). Cancer-associated CAFs in CRC cells upregulate Wnt signaling-related genes, T-lymphoma infiltration and metastasis-inducing protein 1, and ultimately enhance the resistance of CRC by increasing the expression of tumor stem cells (161). BCL-9 serves a key role in promoting chemoresistance via the Wnt signaling pathway (162). Hypoxia in the TME leads to the upregulation of the key Wnt coactivator BCL-9 in a hypoxia-inducible factor-1α/2α-related manner (163). There is crosstalk between Wnt signaling and the hypoxia signaling pathway. This crosstalk synergistically acts on the development of CRC resistance (163).
Immunotherapy targeting TME is an important treatment for CRC (151). Programmed death-1 (PD-1) is a coinhibitory molecule on T cells. The interaction of PD-1 and its ligand PD-L1 affects the use of metabolic substrates and results in T cell failure and immune escape of tumor cells (164). Therefore, monoclonal antibodies that inhibit immune checkpoint receptors, including PD-1, are approved for the treatment of CRC (165). However, a significant proportion of patients remain clinically unresponsive to this treatment (166–168). The occurrence of this low sensitivity may be related to the reduction of pre-existing CD8+ T cells that are negatively regulated by PD-1/PD-L1-mediated adaptive immune resistance (169,170). Notably, Wnt/β-catenin signaling results from the exclusion of CD8+ T cells, which results in resistance to PD-1 inhibitors (171). Abnormal Wnt/β-catenin signaling activation in CRC significantly increases the infiltration of regulatory T cells (Tregs), effective inhibitors of CD8+ T cells. Tregs promote resistance by negating the function of cytotoxic CD8+ T cells (172). In addition to Tregs, dendritic cells (DCs) represent another important component of the immune cells that regulate tumor cell resistance (94). Tumor-resident CD103+ DCs are necessary for the recruitment of CD8+ T cells (171). Blockade of Wnt/β-catenin signaling in CRC cells increases DC infiltration, which leads to a significant increase in active CD8+ T cells in CRC models and the consequent sensitizing of cancer cells to PD-1 inhibitors (172). Overall, these studies suggest that Wnt/β-catenin signaling mediates CRC resistance to immunotherapy via the regulation of immune cells in TME and provides a promising strategy for cancer therapy via the inhibition of Wnt/β-catenin signaling.
Wnt inhibitors reduce the resistance of CRC
A number of Wnt inhibitors avoid resistance to drug recognition and work in conjunction with current clinical front-line drugs for CRC. Several studies are focused on Wnt inhibitors in 5-FU resistance (56,94,173). Coumarin Esculetin (EST) reduces the release of E-cadherin, vimentin, β-catenin, c-Myc, cyclin D1, Wnt3a and VEGF, which inhibit Wnt/β-catenin signaling (174). In vitro and in vivo experiments have shown that EST combined with 5-FU enhances the sensitivity of HT-29, SW480, HCT-116 and Caco-2 CRC cells to 5-FU (174). Similarly, the use of the multikinase inhibitor regorafenib increases miR-34a levels and reverses 5-FU resistance and the cancer-initiating cell phenotype by degrading Wnt/β-catenin in HCT-116R and DLD-1R CRC cells (175). In vitro experimental results showed that the inhibition of the Wnt/β-catenin signaling cascade using the tankyrase inhibitor XAV939 overcomes the resistance of CRC cells carrying short APCs to 5-FU (176). The upregulation of guanylate-binding protein-1 enhances the killing effect of PTX in PTX-sensitive CRC cells and PTX-resistant CRC cells via inhibition of Wnt/β-catenin signaling in the CRC cell lines DLD-1, HT29, DiFi, T84 and HCT116 (177). Wu et al (178) reported that the synergistic use of cinnamaldehyde and L-OHP inhibits hypoxia-activated Wnt/β-catenin signaling, reverses EMT, actives CSC and diminishes the occurrence of L-OHP resistance. Patients with CRC with KRAS mutations are not sensitive to cetuximab and panitumumab (179). The potent and selective Wnt/β-catenin inhibitor KYA1797K activates GSK3β and degrades small β-catenin and Ras molecules to increase the sensitivity of tumors bearing KRAS mutations to cetuximab and panitumumab (180). These results indicate that Wnt signaling leads to chemoresistance in CRC. These studies highlight that the use of Wnt inhibitors affects the chemical sensitivity of cells to other drugs, which provides new approaches for the clinical treatment of CRC.
The role of Wnt/β-catenin signaling crosstalk in resistance
Activation of the checkpoint kinase 1 (CHK1) pathway enhances the drug sensitivity of CRC. He et al (181) performed microarray analysis on CRC-resistant cells and reported that Wnt signaling activation leads to 5-FU resistance via inhibition of the CHK1 pathway in TP53 wild-type cells, such as HCT-8. In addition, period circadian protein homolog 3 and dishevelled-3 are common members of the Wnt/β-catenin pathway and the Notch signaling pathway, which are involved in chemoresistance (182). Experimental inhibition or enhancement of the expression of these genes act on the Wnt/β-catenin signaling and Notch signaling pathways simultaneously to improve drug sensitivity (182,183). These findings highlight the fact that the Wnt/β-catenin signaling pathway and other signaling pathways exhibit crosstalk, synergistic and antagonistic effects in the occurrence of CRC resistance. Common members between these different signaling pathways should be identified as targets to overcome the occurrence of CRC resistance.
Conclusions
CRC is one of the most common malignant tumors in humans, and the survival rate remains low (1). Treatment resistance in CRC remains an unsolved problem (17). Generally, the chemical resistance mechanism of CRC is closely associated with CSCs, ncRNAs and the TME (19–22). Wnt/β-catenin signaling maintains the natural chemical resistance of CSCs and improves drug resistance via the promotion of ABC transporter and glycolysis in CSCs cells (25,119). The interaction between Wnt/β-catenin signaling and ncRNAs regulates the cell cycle and the expression of cancer-related genes (26,131,132). The TME enhances Wnt/β-catenin signaling activity (150). Wnt/β-catenin signaling also mediates tumor immune escape in the TME (151). Therefore, examining the role of Wnt/β-catenin signaling in depth has great potential for therapeutic intervention. More studies should focus on the mechanism of CRC resistance, and robust preclinical drug testing of Wnt inhibitors as a single drug or in combination with CRC is required.
Acknowledgements
Not applicable.
Funding
This study was supported by grants from the Natural Science Foundation of Jiangxi Province (grant no. 20202BABL206089) and the Natural Science Foundation of Department of Education of Jiangxi Province (grant no. GJJ190072).
Availability of data and materials
Not applicable.
Authors' contributions
GXZ, ZZS, LC and WJD collected the related literature and drafted the manuscript. QFY and DG participated in the design of the review and drafted the manuscript. All authors read and approved the final manuscript.
Ethics approval and consent to participate
Not applicable.
Patient consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
ReferencesKeumNGiovannucciEGlobal burden of colorectal cancer: Emerging trends, risk factors and prevention strategies16713732201910.1038/s41575-019-0189-8RawlaPSunkaraTBarsoukAEpidemiology of colorectal cancer: Incidence, mortality, survival, and risk factors14891032019ArnoldMSierraMSLaversanneMSoerjomataramIJemalABrayFGlobal patterns and trends in colorectal cancer incidence and mortality66683691201710.1136/gutjnl-2015-310912MarmolISanchez-de-DiegoCPradilla DiesteACerradaERodriguez YoldiMJColorectal carcinoma: A general overview and future perspectives in colorectal cancer18197201710.3390/ijms18010197CalvertPMFruchtHThe genetics of colorectal cancer137603612200210.7326/0003-4819-137-7-200210010-00012AngaritaFAFeinbergAEFeinbergSMRiddellRHMcCartJAManagement of complex polyps of the colon and rectum33115129201810.1007/s00384-017-2950-1BlankARobertsDEIIDawsonHZlobecILugliATumor heterogeneity in primary colorectal cancer and corresponding metastases52342018DahmusJDKotlerDLKastenbergDMKistlerCAThe gut microbiome and colorectal cancer: A review of bacterial pathogenesis9769777201810.21037/jgo.2018.04.07JayasekaraHEnglishDRHaydonAHodgeAMLynchBMRostyCWilliamsonEJClendenningMSoutheyMCJenkinsMAAssociations of alcohol intake, smoking, physical activity and obesity with survival following colorectal cancer diagnosis by stage, anatomic site and tumor molecular subtype142238250201810.1002/ijc.31049MehtaAPatelBMTherapeutic opportunities in colon cancer: Focus on phosphodiesterase inhibitors230150161201910.1016/j.lfs.2019.05.043SalongaDDanenbergKDJohnsonMMetzgerRGroshenSTsao-WeiDDLenzHJLeichmanCGLeichmanLDiasioRBDanenbergPVColorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase6132213272000ShowalterSLShowalterTNWitkiewiczAHavensRKennedyEPHuclTKernSEYeoCJBrodyJREvaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil7986994200810.4161/cbt.7.7.6181YaffeePOsipovATanCTuliRHendifarAReview of systemic therapies for locally advanced and metastatic rectal cancer61852002015CunninghamDHumbletYSienaSKhayatDBleibergHSantoroABetsDMueserMHarstrickAVerslypeCCetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer351337345200410.1056/NEJMoa033025Van CutsemEPeetersMSienaSHumbletYHendliszANeynsBCanonJLVan LaethemJLMaurelJRichardsonGOpen-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer2516581664200710.1200/JCO.2006.08.1620HuTLiZGaoCYChoCHMechanisms of drug resistance in colon cancer and its therapeutic strategies2268766889201610.3748/wjg.v22.i30.6876LiYJLeiYHYaoNWangCRHuNYeWCZhangDMChenZSAutophagy and multidrug resisitance in cancer3652201710.1186/s40880-017-0219-2ThomasHColeyHMOvercoming multidrug resistance in cancer: An update on the clinical strategy of inhibiting p-glycoprotein10159165200310.1177/107327480301000207TredanOGalmariniCMPatelKTannockIFDrug resistance and the solid tumor microenvironment9914411454200710.1093/jnci/djm135WangMYQiuYHCaiMLZhangCHWangXWLiuHChenYZhaoWLLiuJBShaoRGRole and molecular mechanism of stem cells in colorectal cancer initiation28110202010.1080/1061186X.2019.1632317LiuXFuQDuYYangYChoWCMicroRNA as regulators of cancer stem cells and chemoresistance in colorectal cancer16738754201610.2174/1568009616666151118114759FanaleDBarracoNListiABazanVRussoANon-coding RNAs functioning in colorectal cancer stem cells93793108201610.1007/978-3-319-42059-2_5RahmaniFAvanAHashemySIHassanianSMRole of Wnt/beta-catenin signaling regulatory microRNAs in the pathogenesis of colorectal cancer233811817201810.1002/jcp.25897DasPKIslamFLamAKThe roles of cancer stem cells and therapy resistance in colorectal carcinoma91392202010.3390/cells9061392ChikazawaNTanakaHTasakaTNakamuraMTanakaMOnishiHKatanoMInhibition of Wnt signaling pathway decreases chemotherapy-resistant side-population colon cancer cells30204120482010ShiLXiJXuXPengBZhangBMiR-148a suppressed cell invasion and migration via targeting WNT10b and modulating β-catenin signaling in cisplatin-resistant colorectal cancer cells109902909201910.1016/j.biopha.2018.10.080HuYBYanCMuLMiYLZhaoHHuHLiXLTaoDDWuYQGongJPQinJCExosomal Wnt-induced dedifferentiation of colorectal cancer cells contributes to chemotherapy resistance3819511965201910.1038/s41388-019-0863-xNusseRVarmusHEMany tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome3199109198210.1016/0092-8674(82)90409-3RijsewijkFSchuermannMWagenaarEParrenPWeigelDNusseRThe Drosophila homolog of the mouse mammary oncogene int-1 is identical to the segment polarity gene wingless50649657198710.1016/0092-8674(87)90038-9KahnMCan we safely target the WNT pathway?13513532201410.1038/nrd4233ZengZYZhouYHZhangWLXiongWFanSQLiXLLuoXMWuMHYangYXHuangCGene expression profiling of nasopharyngeal carcinoma reveals the abnormally regulated Wnt signaling pathway38120133200710.1016/j.humpath.2006.06.023PateKTStringariCSprowl-TanioSWangKTeSlaaTHoverterNPMcQuadeMMGarnerCDigmanMATeitellMAWnt signaling directs a metabolic program of glycolysis and angiogenesis in colon cancer3314541473201410.15252/embj.201488598PolakisPWnt signaling in cancer4a008052201210.1101/cshperspect.a008052TammelaTSanchez-RiveraFJCetinbasNMWuKJoshiNSHeleniusKParkYAzimiRKerperNRWesselhoeftRAA Wnt-producing niche drives proliferative potential and progression in lung adenocarcinoma545355359201710.1038/nature22334LeeSYJeonHMJuMKKimCHYoonGHanSIParkHGKangHSWnt/Snail signaling regulates cytochrome C oxidase and glucose metabolism7236073617201210.1158/0008-5472.CAN-12-0006WillertKBrownJDDanenbergEDuncanAWWeissmanILReyaTYatesJRIIINusseRWnt proteins are lipid-modified and can act as stem cell growth factors423448452200310.1038/nature01611TakadaRSatomiYKurataTUenoNNoriokaSKondohHTakaoTTakadaSMonounsaturated fatty acid modification of Wnt protein: Its role in Wnt secretion11791801200610.1016/j.devcel.2006.10.003HeBYouLUematsuKXuZLeeAYMatsangouMMcCormickFJablonsDMA monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells6714200410.1016/S1476-5586(04)80048-4ChenGShukeirNPottiASircarKAprikianAGoltzmanDRabbaniSAUp-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: Potential pathogenetic and prognostic implications10113451356200410.1002/cncr.20518BabaeiKKhaksarRZeinaliTHemmatiHBandegiASamidoustPAshoobiMTHashemianHDelpasandKTalebinasabFEpigenetic profiling of MUTYH, KLF6, WNT1 and KLF4 genes in carcinogenesis and tumorigenesis of colorectal cancer922201910.1051/bmdcn/2019090422JiaSQuTFengMJiKLiZJiangWJiJAssociation of Wnt1-inducible signaling pathway protein-1 with the proliferation, migration and invasion in gastric cancer cells391010428317699755201710.1177/1010428317699755BodnarLStanczakACierniakSSmoterMCichowiczMKozlowskiWSzczylikCWieczorekMLamparska-PrzybyszMWnt/β-catenin pathway as a potential prognostic and predictive marker in patients with advanced ovarian cancer716201410.1186/1757-2215-7-16HuangCBMaRJXuYLiNLiZXYueJLiHXGuoYQiDWnt2 promotes non-small cell lung cancer progression by activating WNT/β-catenin pathway5103210462015KatohMFrequent up-regulation of WNT2 in primary gastric cancer and colorectal cancer19100310072001NakashimaNLiuDHuangCLUenoMZhangXYokomiseHWnt3 gene expression promotes tumor progression in non-small cell lung cancer76228234201210.1016/j.lungcan.2011.10.007WangHSNieXWuRBYuanHWMaYHLiuXLZhangJYDengXLNaQJinHYDownregulation of human Wnt3 in gastric cancer suppresses cell proliferation and induces apoptosis938493860201610.2147/OTT.S101782NieXBXiaFLLiuYZhouYYeWLHeanPHMengJMLiuHYLiuLWenJXDownregulation of Wnt3 suppresses colorectal cancer development through inhibiting cell proliferation and migration101110201910.3389/fphar.2019.01110ThiagoLCostaESLopesDVOtazuIBNowillAEMendesFAPortilhoDMAbreuJGMermelsteinCSOrfaoAThe Wnt signaling pathway regulates Nalm-16 b-cell precursor acute lymphoblastic leukemic cell line survival and etoposide resistance646372201010.1016/j.biopha.2009.09.005ZimmermanZFKulikauskasRMBomsztykKMoonRTChienAJActivation of Wnt/β-catenin signaling increases apoptosis in melanoma cells treated with trail8e69593201310.1371/journal.pone.0069593AnnavarapuSRCialfiSDominiciCKokaiGKUcciniSCeccarelliSMcDowellHPHelliwellTRCharacterization of Wnt/β-catenin signaling in rhabdomyosarcoma9310901099201310.1038/labinvest.2013.97FoxSARichardsAKKusumahIPerumalVBolithoEMMutsaersSEDharmarajanAMExpression profile and function of Wnt signaling mechanisms in malignant mesothelioma cells4408287201310.1016/j.bbrc.2013.09.025WangSHLiNWeiYLiQRYuZPβ-catenin deacetylation is essential for WNT-induced proliferation of breast cancer cells9973978201410.3892/mmr.2014.1889AkaboshiSWatanabeSHinoYSekitaYXiYArakiKYamamuraKOshimaMItoTBabaHNakaoMHMGA1 is induced by Wnt/beta-catenin pathway and maintains cell proliferation in gastric cancer17516751685200910.2353/ajpath.2009.090069ZhaoLWangLLZhangCLLiuZPiaoYJYanJXiangRYaoYQYSE6-induced selective translation of WNT4 and JIP2 promotes the progression of cervical cancer via a noncanonical WNT signaling pathway432201910.1038/s41392-019-0060-yMcDonaldSLSilverAThe opposing roles of Wnt-5a in cancer101209214200910.1038/sj.bjc.6605174LiJYingJFanYWuLYingYChanATSrivastavaGTaoQWNT5A antagonizes WNT/β-catenin signaling and is frequently silenced by promoter CpG methylation in esophageal squamous cell carcinoma10617624201010.4161/cbt.10.6.12609YingJLiHYuJNgKMPoonFFWongSCChanATSungJJTaoQWNT5A exhibits tumor-suppressive activity through antagonizing the Wnt/beta-catenin signaling, and is frequently methylated in colorectal cancer145561200810.1158/1078-0432.CCR-07-1644KremenevskajaNvon WasielewskiRRaoASSchoflCAnderssonTBrabantGWnt-5a has tumor suppressor activity in thyroid carcinoma2421442154200510.1038/sj.onc.1208370ThieleSRachnerTDRaunerMHofbauerLCWNT5A and its receptors in the bone-cancer dialogue3114881496201610.1002/jbmr.2899KurayoshiMOueNYamamotoHKishidaMInoueAAsaharaTYasuiWKikuchiAExpression of Wnt-5a is correlated with aggressiveness of gastric cancer by stimulating cell migration and invasion661043910448200610.1158/0008-5472.CAN-06-2359HuangCLLiuDNakanoJIshikawaSKontaniKYokomiseHUenoMWnt5a expression is associated with the tumor proliferation and the stromal vascular endothelial growth factor-an expression in non-small-cell lung cancer2387658773200510.1200/JCO.2005.02.2871BoHZhangSGaoLChenYZhangJChangXZhuMUpregulation of Wnt5a promotes epithelial-tomesenchymal transition and metastasis of pancreatic cancer cells13496201310.1186/1471-2407-13-496Navarrete-MenesesMDPPerez-VeraPEpigenetic alterations in acute lymphoblastic leukemia742432642017(In Spanish)StewartDJWnt signaling pathway in non-small cell lung cancer106djt356201410.1093/jnci/djt356KirikoshiHKatohMExpression of WNT7A in human normal tissues and cancer, and regulation of WNT7A and WNT7B in human cancer218959002002VeselMRappJFellerDKissEJaromiLMeggyesMMiskeiGDugaBSmukGLaszloTABCB1 and ABCG2 drug transporters are differentially expressed in non-small cell lung cancers (NSCLC) and expression is modified by cisplatin treatment via altered Wnt signaling1852201710.1186/s12931-017-0537-6LiJZhangZWangLZhangYThe oncogenic role of Wnt10a in colorectal cancer through activation of canonical Wnt/β-catenin signaling17365736642019LiPLiuWXuQWangCClinical significance and biological role of Wnt10a in ovarian cancer14661166172017HsuRJHoJYChaTLYuDSWuCLHuangWPChuPChenYHChenJTYuCPWNT10A plays an oncogenic role in renal cell carcinoma by activating WNT/beta-catenin pathway7e47649201210.1371/journal.pone.0047649KirikoshiHInoueSSekiharaHKatohMExpression of WNT10A in human cancer1999710012001DongTZhangZZhouWZhouXGengCChangLKTianXLiuSWNT10A/β-catenin pathway in tumorigenesis of papillary thyroid carcinoma3812871294201710.3892/or.2017.5777WendPRunkeSWendKAnchondoBYesayanMJardonMHardieNLoddenkemperCUlasovILesniakMSWNT10B/beta-catenin signalling induces HMGA2 and proliferation in metastatic triple-negative breast cancer5264279201310.1002/emmm.201201320ChenHWangYXueFExpression and the clinical significance of Wnt10a and Wnt10b in endometrial cancer are associated with the Wnt/β-catenin pathway29507514201310.3892/or.2012.2126SaitohTKirikoshiHMineTKatohMProto-oncogene WNT10B is up-regulated by tumor necrosis factor alpha in human gastric cancer cell line MKN4519118711922001BartisDCsongeiVWeichAKissEBarkoSKovacsTAvdicevicMD'SouzaVKRappJKvellKDown-regulation of canonical and up-regulation of non-canonical Wnt signalling in the carcinogenic process of squamous cell lung carcinoma8e57393201310.1371/journal.pone.0057393TianSHuJTaoKWangJChuYLiJLiuZDingXXuLLiQSecreted AGR2 promotes invasion of colorectal cancer cells via Wnt11-mediated non-canonical Wnt signaling364198207201810.1016/j.yexcr.2018.02.004ToyamaTLeeHCKogaHWandsJRKimMNoncanonical Wnt11 inhibits hepatocellular carcinoma cell proliferation and migration8254265201010.1158/1541-7786.MCR-09-0238YinPWangWZhangZBaiYGaoJZhaoCWnt signaling in human and mouse breast cancer: Focusing on Wnt ligands, receptors and antagonists10933683375201810.1111/cas.13771BarkerNvan EsJHKuipersJKujalaPvan den BornMCozijnsenMHaegebarthAKorvingJBegthelHPetersPJCleversHIdentification of stem cells in small intestine and colon by marker gene Lgr544910031007200710.1038/nature06196BourroulGMFragosoHJGomesJWBourroulVSOshimaCTGomesTSSabaGTPalmaRTWaisbergJThe destruction complex of beta-catenin in colorectal carcinoma and colonic adenoma14135142201610.1590/S1679-45082016AO3678SawaMMasudaMYamadaTTargeting the Wnt signaling pathway in colorectal cancer20419429201610.1517/14728222.2016.1098619AmitSHatzubaiABirmanYAndersenJSBen-ShushanEMannMBen-NeriahYAlkalayIAxin-mediated CKI phosphorylation of beta-catenin at Ser 45: A molecular switch for the Wnt pathway1610661076200210.1101/gad.230302HeXSemenovMTamaiKZengXLDL receptor-related proteins 5 and 6 in Wnt/beta-catenin signaling: Arrows point the way13116631677200410.1242/dev.01117BilicJHuangYLDavidsonGZimmermannTCruciatCMBienzMNiehrsCWnt induces LRP6 signalosomes and promotes dishevelled-dependent LRP6 phosphorylation31616191622200710.1126/science.1137065ZarkouVGalarasAGiakountisAHatzisPCrosstalk mechanisms between the WNT signaling pathway and long non-coding RNAs34253201810.1016/j.ncrna.2018.04.001HammondWASwaikaAModyKPharmacologic resistance in colorectal cancer: A review85784201610.1177/1758834015614530GheidariFBakhshandehBTeimoori-ToolabiLMehrtashAGhadirMZeinaliSTCF4 silencing sensitizes the colon cancer cell line to oxaliplatin as a common chemotherapeutic drug25908916201410.1097/CAD.0000000000000118KosuriKVWuXWangLVillalona-CaleroMAOttersonGAAn epigenetic mechanism for capecitabine resistance in mesothelioma39114651470201010.1016/j.bbrc.2009.12.095RiethJSubramanianSMechanisms of intrinsic tumor resistance to immunotherapy191340201810.3390/ijms19051340GhadimiBMGradeMDifilippantonioMJVarmaSSimonRMontagnaCFuzesiLLangerCBeckerHLierschTRiedTEffectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy2318261838200510.1200/JCO.2005.00.406EmonsGSpitznerMReinekeSMollerJAuslanderNKramerFHuYBeissbarthTWolffHARave-FrankMChemoradiotherapy resistance in colorectal cancer cells is mediated by Wnt/beta-catenin signaling1514811490201710.1158/1541-7786.MCR-17-0205DengYHPuXXHuangMJXiaoJZhouJMLinTYLinEH5-Fluorouracil upregulates the activity of Wnt signaling pathway in CD133-positive colon cancer stem-like cells29810815201010.5732/cjc.010.10134VaishVKimJShimMJagged-2 (JAG2) enhances tumorigenicity and chemoresistance of colorectal cancer cells85326253275201710.18632/oncotarget.18391KukcinaviciuteEJonusieneVSasnauskieneADabkevicieneDEidenaiteELaurinaviciusASignificance of Notch and Wnt signaling for chemoresistance of colorectal cancer cells HCT11611959135920201810.1002/jcb.26783Gonzalez-ExpositoRSemiannikovaMGriffithsBKhanKBarberLJWoolstonASpainGvon LogaKChallonerBPatelRCEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids7101201910.1186/s40425-019-0575-3ChangTCYehCTAdebayoBOLinYCDengLRaoYKHuangCCLeeWHWuATHsiaoM4-Acetylantroquinonol B inhibits colorectal cancer tumorigenesis and suppresses cancer stem-like phenotype288258268201510.1016/j.taap.2015.07.025VermeulenLSprickMRKemperKStassiGMedemaJPCancer stem cells-old concepts, new insights15947958200810.1038/cdd.2008.20MunroMJWickremesekeraSKPengLTanSTItinteangTCancer stem cells in colorectal cancer: A review71110116201810.1136/jclinpath-2017-204739LiNBabaei-JadidiRLorenziFSpencer-DeneBClarkePDomingoETulchinskyEVriesRGJKerrDPanYAn FBXW7-ZEB2 axis links EMT and tumour microenvironment to promote colorectal cancer stem cells and chemoresistance813201910.1038/s41389-019-0125-3Prieti-VilaMTakahashiRUsubaWKohamaIOchiyaTDrug resistance driven by cancer stem cells and their niche182574201710.3390/ijms18122574LiLXieTStem cell niche: Structure and function21605631200510.1146/annurev.cellbio.21.012704.131525LiuHZhangWJiaYYuQGrauGEPengLRanYYangZDengHLouJSingle-cell clones of liver cancer stem cells have the potential of differentiating into different types of tumor cells4e857201310.1038/cddis.2013.340DavereyADrainAPKidambiSPhysical intimacy of breast cancer cells with mesenchymal stem cells elicits trastuzumab resistance through src activation513744201510.1038/srep13744KimJYLeeHYParkKKChoiYKNamJSHongISCWP232228 targets liver cancer stem cells through Wnt/β-catenin signaling: A novel therapeutic approach for liver cancer treatment72039520409201610.18632/oncotarget.7954FevrTRobineSLouvardDHuelskenJWnt/beta-catenin is essential for intestinal homeostasis and maintenance of intestinal stem cells2775517559200710.1128/MCB.01034-07Dahal LamichaneBJungSYYunJKangSKimDYLamichaneSKimYJParkJHJangWBJiSTAGR2 is a target of canonical Wnt/β-catenin signaling and is important for stemness maintenance in colorectal cancer stem cells515600606201910.1016/j.bbrc.2019.05.154LiuYSHsuHCTsengKCChenHCChenSJLgr5 promotes cancer stemness and confers chemoresistance through ABCB1 in colorectal cancer67791799201310.1016/j.biopha.2013.08.001ZhanTAmbrosiGWandmacherAMRauscherBBetgeJRindtorffNHausslerRSHinsenkampIBambergLHesslingBMEK inhibitors activate Wnt signalling and induce stem cell plasticity in colorectal cancer102197201910.1038/s41467-019-09898-0WuWCaoJJiZWangJJiangTDingHCo-expression of Lgr5 and CXCR4 characterizes cancer stem-like cells of colorectal cancer78114481155201610.18632/oncotarget.13214KobayashiSYamada-OkabeHSuzukiMNatoriOKatoAMatsubaraKJau ChenYYamazakiMFunahashiSYoshidaKLGR5-positive colon cancer stem cells interconvert with drug-resistant LGR5-negative cells and are capable of tumor reconstitution3026312644201210.1002/stem.1257Villanueva-ToledoJPonciano-GomezAOrtiz-SanchezEGarridoESide populations from cervical-cancer-derived cell lines have stem-cell-like properties4119932004201410.1007/s11033-014-3047-3SteinbichlerTBDudasJSkvortsovSGanswindtURiechelmannHSkvortsovaIITherapy resistance mediated by cancer stem cells53156167201810.1016/j.semcancer.2018.11.006SinghASettlemanJEMT, cancer stem cells and drug resistance: An emerging axis of evil in the war on cancer2947414751201010.1038/onc.2010.215Martin-OrozcoESanchez-FernandezAOrtiz-ParraIAyala-San NicolasMWNT signaling in tumors: The way to evade drugs and immunity102854201910.3389/fimmu.2019.02854IslamMOKanemuraYTajriaJMoriHKobayashiSShofudaTMiyakeJHaraMYamasakiMOkanoHCharacterization of ABC transporter ABCB1 expressed in human neural stem/progenitor cells57934733480200510.1016/j.febslet.2005.05.019FalascaMLintonKJInvestigational ABC transporter inhibitors21657666201210.1517/13543784.2012.679339DuanZLiXHuangHYuanWZhengSLLiuXZhangZChoyEHarmonDMankinHHornicekFSynthesis and evaluation of (2-(4-methoxyphenyl)-4-quinolinyl)(2-piperidinyl)methanol (NSC23925) isomers to reverse multidrug resistance in cancer5531133121201210.1021/jm300117uHuangXCSunYLSalimAAChenZSCaponRJParguerenes: Marine red alga bromoditerpenes as inhibitors of P-glycoprotein (ABCB1) in multidrug resistant human cancer cells8512571268201310.1016/j.bcp.2013.02.005ZinziLContinoMCantoreMCapparelliELeopoldoMColabufoNAABC transporters in CSCs membranes as a novel target for treating tumor relapse5163201410.3389/fphar.2014.00163LiuYYGuptaVPatwardhanGABhingeKZhaoYBaoJMehendaleHCabotMCLiYTJazwinskiSMGlucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling9145201010.1186/1476-4598-9-145KugimiyaNNishimotoAHosoyamaTUenoKEnokiTLiTSHamanoKThe c-MYC-ABCB5 axis plays a pivotal role in 5-fluorouracil resistance in human colon cancer cells1915691581201510.1111/jcmm.12531WangTChenZZhuYPanQLiuYQiXJinLJinJMaXHuaDInhibition of transient receptor potential channel 5 reverses 5-Fluorouracil resistance in human colorectal cancer cells290448456201510.1074/jbc.M114.590364PlaksVKongNWerbZThe cancer stem cell niche: How essential is the niche in regulating stemness of tumor cells?16225238201510.1016/j.stem.2015.02.015OsthusRCShimHKimSLiQReddyRMukherjeeMXuYWonseyDLeeLADangCVDeregulation of glucose transporter 1 and glycolytic gene expression by c-Myc2752179721800200010.1074/jbc.C000023200WangTNingKLuTXHuaDElevated expression of TrpC5 and GLUT1 is associated with chemoresistance in colorectal cancer3710591065201710.3892/or.2016.5322MatsuiMCoreyDRNon-coding RNAs as drug targets16167179201710.1038/nrd.2016.117LingHFabbriMCalinGAMicroRNAs and other non-coding RNAs as targets for anticancer drug development12847865201310.1038/nrd4140LaurentGSWahlestedtCKapranovPThe landscape of long noncoding RNA classification31239251201510.1016/j.tig.2015.03.007Sato-KuwabaraYMeloSASoaresFACalinGAThe fusion of two worlds: Non-coding RNAs and extracellular vesicles-diagnostic and therapeutic implications (Review)461727201510.3892/ijo.2014.2712EbbesenKKKjemsJHansenTBCircular RNAs: Identification, biogenesis and function1859163168201610.1016/j.bbagrm.2015.07.007ChenHYLangYDLinHNLiuYRLiaoCCNanaAWYenYChenRHmiR-103/107 prolong Wnt/β-catenin signaling and colorectal cancer stemness by targeting Axin299687201910.1038/s41598-019-41053-zZhouHLinCZhangYZhangXZhangCZhangPXieXRenZmiR-506 enhances the sensitivity of human colorectal cancer cells to oxaliplatin by suppressing MDR1/P-gp expression50e12341201710.1111/cpr.12341LuMLZhangYLiJFuYLiWHZhaoGFLiXHWeiLLiuGBHuangHMicroRNA-124 inhibits colorectal cancer cell proliferation and suppresses tumor growth by interacting with PLCB1 and regulating Wnt/β-catenin signaling pathway231211362019LiangCQFuYMLiuZYXingBRJinYHuangJLThe effect of miR-224 down-regulation on SW80 cell proliferation and apoptosis and weakening of ADM drug resistance21500850162017LuceroOMDawsonDWMoonRTChienAJA re-evaluation of the ‘oncogenic’ nature of Wnt/beta-catenin signaling in melanoma and other cancers12314318201010.1007/s11912-010-0114-3SongCLuPSunGYangLWangZWangZmiR-34a sensitizes lung cancer cells to cisplatin via p53/miR-34a/MYCN axis4822227201710.1016/j.bbrc.2016.11.037Schulz-HeddergottRStarkNEdmundsSJLiJConradiLCBohnenbergerHCeteciFGretenFRDobbelsteinMMollUMTherapeutic ablation of gain-of-function mutant p53 in colorectal cancer inhibits stat3-mediated tumor growth and invasion34298314 e297201810.1016/j.ccell.2018.07.004NakayamaMSakaiEEchizenKYamadaYOshimaHHanTSOhkiRFujiiSOchiaiARobineSIntestinal cancer progression by mutant p53 through the acquisition of invasiveness associated with complex glandular formation3658855896201710.1038/onc.2017.194LaneDPCheokCFLainSp53-based cancer therapy2a001222201010.1101/cshperspect.a001222TsouSHHouMHHsuLCChenTMChenYHGain-of-function p53 mutant with 21-bp deletion confers susceptibility to multidrug resistance in MCF-7 cells37233242201610.3892/ijmm.2015.2406LiXLZhouJChenZRChngWJP53 mutations in colorectal cancer-molecular pathogenesis and pharmacological reactivation218493201510.3748/wjg.v21.i1.84KwakBKimDUKimTOKimHSKimSWMicroRNA-552 links Wnt signaling to p53 tumor suppressor in colorectal cancer53180018082018ZhouADDiaoLTXuHXiaoZDLiJHZhouHQuLHβ-Catenin/LEF1 transactivates the microRNA-371-373 cluster that modulates the Wnt/β-catenin-signaling pathway3129682978201210.1038/onc.2011.461WangLQYuPLiBGuoYHLiangZRZhengLLYangJHXuHLiuSZhengLSmiR-372 and miR-373 enhance the stemness of colorectal cancer cells by repressing differentiation signaling pathways1219491964201810.1002/1878-0261.12376HanPLiJWZhangBMLvJCLiYMGuXYYuZWJiaYHBaiXFLiLThe lncRNA CRNDE promotes colorectal cancer cell proliferation and chemoresistance via miR-181a-5p-mediated regulation of Wnt/β-catenin signaling169201710.1186/s12943-017-0583-1XiaoZQuZChenZFangZZhouKHuangZGuoXZhangYLncRNA HOTAIR is a prognostic biomarker for the proliferation and chemoresistance of colorectal cancer via MiR-203a-3p-mediated Wnt/ß-catenin signaling pathway4612751285201810.1159/000489110WuKFLiangWCFengLPangJXWayeMMZhangJFFuWMH19 mediates methotrexate resistance in colorectal cancer through activating Wnt/β-catenin pathway350312317201710.1016/j.yexcr.2016.12.003DengXRuanHZhangXXuXZhuYPengHZhangXKongFGuanMLong noncoding RNA CCAL transferred from fibroblasts by exosomes promotes chemoresistance of colorectal cancer cells14617001716202010.1002/ijc.32608MaYYangYWangFMoyerMPWeiQZhangPYangZLiuWZhangHChenNLong non-coding RNA CCAL regulates colorectal cancer progression by activating Wnt/β-catenin signalling pathway via suppression of activator protein 2α6514941504201610.1136/gutjnl-2014-308392HanahanDCoussensLMAccessories to the crime: Functions of cells recruited to the tumor microenvironment21309322201210.1016/j.ccr.2012.02.022SunYTumor microenvironment and cancer therapy resistance380205215201610.1016/j.canlet.2015.07.044CastelloneMDTeramotoHWilliamsBODrueyKMGutkindJSProstaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis31015041510200510.1126/science.1116221YangLLinCLiuZRP68 RNA helicase mediates PDGF-induced epithelial mesenchymal transition by displacing Axin from beta-catenin127139155200610.1016/j.cell.2006.08.036GuptaGPMassagueJCancer metastasis: Building a framework127679695200610.1016/j.cell.2006.11.001GrossJCChaudharyVBartschererKBoutrosMActive Wnt proteins are secreted on exosomes1410361045201210.1038/ncb2574HuJLWangWLanXLZengZCLiangYSYanYRSongFYWangFFZhuXHLiaoWJCAFs secreted exosomes promote metastasis and chemotherapy resistance by enhancing cell stemness and epithelial-mesenchymal transition in colorectal cancer1891201910.1186/s12943-019-1019-xXuXChangWYuanJHanXTanXDingYLuoYCaiHLiuYGaoXPeriostin expression in intra-tumoral stromal cells is prognostic and predictive for colorectal carcinoma via creating a cancer-supportive niche7798813201610.18632/oncotarget.5985SunYCampisiJHiganoCBeerTMPorterPColemanITrueLNelsonPSTreatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B1813591368201210.1038/nm.2890SunYZhuDChenFQianMWeiHChenWXuJSFRP2 augments WNT16B signaling to promote therapeutic resistance in the damaged tumor microenvironment3543214334201610.1038/onc.2015.494IzumiDTodenSUretaEIshimotoTBabaHGoelATIAM1 promotes chemoresistance and tumor invasiveness in colorectal cancer10267201910.1038/s41419-019-1493-5TakadaKZhuDBirdGHSukhdeoKZhaoJJManiMLemieuxMCarrascoDERyanJHorstDTargeted disruption of the BCL9/β-catenin complex inhibits oncogenic Wnt signaling4148ra117201210.1126/scitranslmed.3003808TanZHuangQZangJTengSFChenTRWeiHFSongDWLiuTLYangXHFuCGHIF-1α activates hypoxia-induced BCL-9 expression in human colorectal cancer cells82588525896201710.18632/oncotarget.8834WuXGuZChenYChenBChenWWengLLiuXApplication of PD-1 blockade in cancer immunotherapy17661674201910.1016/j.csbj.2019.03.006YaghoubiNSoltaniAGhazviniKHassanianSMHashemySIPD-1/PD-L1 blockade as a novel treatment for colorectal cancer110312318201910.1016/j.biopha.2018.11.105PayandehZKhaliliSSomiMHMard-SoltaniMBaghbanzadehAHajiasgharzadehKSamadiNBaradaranBPD-1/PD-L1-dependent immune response in colorectal cancer23554615475202010.1002/jcp.29494TopalianSLTaubeJMAndersRAPardollDMMechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy16275287201610.1038/nrc.2016.36GalonJCostesASanchez-CaboFKirilovskyAMlecnikBLagorce-PagesCTosoliniMCamusMBergerAWindPType, density, and location of immune cells within human colorectal tumors predict clinical outcome31319601964200610.1126/science.1129139TumehPCHarviewCLYearleyJHShintakuIPTaylorEJRobertLChmielowskiBSpasicMHenryGCiobanuVPD-1 blockade induces responses by inhibiting adaptive immune resistance515568571201410.1038/nature13954SprangerSKoblishHKHortonBScherlePANewtonRGajewskiTFMechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment23201410.1186/2051-1426-2-3SprangerSDaiDHortonBGajewskiTFTumor-residing Batf3 dendritic cells are required for effector t cell trafficking and adoptive t cell therapy31711723201710.1016/j.ccell.2017.04.003FengMJinJQXiaLXiaoTMeiSWangXHuangXChenJLiuMChenCPharmacological inhibition of β-catenin/BCL9 interaction overcomes resistance to immune checkpoint blockades by modulating T reg5eaau5240201910.1126/sciadv.aau5240BottcherJPReis e SousaCThe role of type 1 conventional dendritic cells in cancer immunity4784792201810.1016/j.trecan.2018.09.001LiuKLiJWuXChenMLuoFLiJGSK-3β inhibitor 6-bromo-indirubin-3′-oxime promotes both adhesive activity and drug resistance in colorectal cancer cells5118211830201710.3892/ijo.2017.4163YanLYuHHLiuYSWangYSZhaoWHEsculetin enhances the inhibitory effect of 5-Fluorouracil on the proliferation, migration and epithelial-mesenchymal transition of colorectal cancer24231240201910.3233/CBM-181764CaiMHXuXGYanSLSunZYingYWangBKTuYXRegorafenib suppresses colon tumorigenesis and the generation of drug resistant cancer stem-like cells via modulation of miR-34a associated signaling37151201810.1186/s13046-018-0836-xSirajAKKumar ParvathareddySPratheeshkumarPPadmaja DivyaSAhmedSOMelosantosRBegumRConcepcionRAl-SaneaNAshariLHAPC truncating mutations in middle eastern population: Tankyrase inhibitor is an effective strategy to sensitize APC mutant CRC To 5-FU chemotherapy121109572202010.1016/j.biopha.2019.109572WangJMinHHuBXueXLiuYGuanylate-binding protein-2 inhibits colorectal cancer cell growth and increases the sensitivity to paclitaxel of paclitaxel-resistant colorectal cancer cells by interfering Wnt signaling12112501259202010.1002/jcb.29358WuCEZhuangYWZhouJYLiuSLWangRPShuPCinnamaldehyde enhances apoptotic effect of oxaliplatin and reverses epithelial-mesenchymal transition and stemnness in hypoxic colorectal cancer cells383111500201910.1016/j.yexcr.2019.111500ZhaoBWangLQiuHZhangMSunLPengPYuQYuanXMechanisms of resistance to anti-EGFR therapy in colorectal cancer839804000201710.18632/oncotarget.14012SansomOJMenielVWilkinsJAColeAMOienKAMarshVJamiesonTJGuerraCAshtonGHBarbacidMClarkeARLoss of Apc allows phenotypic manifestation of the transforming properties of an endogenous K-ras oncogene in vivo1031412214127200610.1073/pnas.0604130103HeLZhuHZhouSWuTWuHYangHMaoHSekharKatheraCJanardhanAEdickAMWnt pathway is involved in 5-FU drug resistance of colorectal cancer cells50101201810.1038/s12276-018-0128-8ZhaoQZhuangKHanKTangHWangYSiWYangZSilencing DVL3 defeats MTX resistance and attenuates stemness via Notch signaling pathway in colorectal cancer216152964202010.1016/j.prp.2020.152964ZhangFSunHZhangSYangXZhangGSuTOverexpression of PER3 inhibits self-renewal capability and chemoresistance of colorectal cancer stem-like cells via inhibition of notch and β-catenin signaling25709719201710.3727/096504016X14772331883976
Schematic representation of the Wnt/β-catenin signaling pathway. (A) Wnt-off state. Cytoplasmic β-catenin is phosphorylated by a destructive complex composed of Axin, APC, GSK3β and CK1, then it is ubiquitinated and targeted for proteasome degradation. (B) Wnt-on state. Binding of Wnt ligands and its receptor Dvl determines the destruction of the β-catenin destruction complex, which induces the stability of β-catenin. β-catenin is transferred to the nucleus as a cofactor of TCF/LEF to activate Wnt target gene. Dvl, Dishevelled; APC, αdenomatous polyposis coli; GSK3β, glycogen synthase kinase 3β; CK1, casein kinase 1; Dvl, Fzd/LRP5/6/Dishevelled; TCF/LEF, transcription factor/lymphocyte-enhancing factor binding factor; Fzd, Frizzled; LRP5/6, low-density lipoprotein-related receptor 5/6.
CAFs stimulate CRC cells to restore CSCs characteristics. CAFs are similar to CRC cells. CAFs secrete exosomes that carry Wnts, which stimulate differentiated CRC cells to restore their CSCs properties, including the expression of CSCs markers and increased Wnt activity. This process contributes to the development of drug resistance. CAFs, cancer-associated fibroblasts; CSCs, tumor stem cells; CRC, colorectal cancer; Fzd, Frizzled; TCF/LEF, transcription factor/lymphocyte-enhancing factor-binding factor; SFRP2, stable free radical polymerization 2.
CAFs act on the Wnt pathway to promote tumor development. DNA damage caused by chemotherapy may result in CAF production of Wnt16B and SFRP2. Wnt16B promotes tumor growth via activation of the canonical pathway in cancer cells, which reduces treatment sensitivity. SFRP2 acts as a synergistic effector. SFRP2 may also participate in non-canonical pathways, such as angiogenesis, which indirectly promotes tumor development. CAFs, cancer-associated fibroblasts; Fzd, Frizzled; SFRP2, stable free radical polymerization 2.
Cancer types associated with the Wnt ligand genes.
Author, year
Gene
Function
Type of cancer
(Refs.)
He et al, 2004 Chen et al, 2004; Babaei et al, 2019 Jia et al, 2017; Bodnar et al, 2014
Wnt1
GOF
Non-small-cell lung, prostate, CRC, gastric and ovarian cancer
(38–42)
Huang et al, 2015; Katoh et al, 2001
Wnt2
GOF
Lung, prostate, gastric cancer and CRC
(43,44)
Nakashima et al, 2012; Wang et al, 2016 Nie et al, 2019
Wnt3
GOF
Lung, CRC and gastric cancer
(45–47)
Thiago et al, 2010 Zimmerman et al, 2013 Annavarapu et al, 2013
Wnt3a
LOF
B cell precursor acute lymphoblastic leukemia, multiple melanoma and alveolar rhabdomyosarcoma
(48–50)
Fox et al, 2013; Wang et al, 2014 Akaboshi et al, 2009
Wnt3a
GOF
Malignant mesothelioma, breast and pancreatic cancer
(51–53)
Zhao et al, 2019
Wnt4
GOF
Cervical cancer
(54)
McDonald et al, 2009; Li et al, 2010 Ying et al, 2008 Kremenevskaja et al, 2005 Thiele et al, 2016; Kurayoshi et al, 2006
Wnt5a
LOF
Prostate and breast cancer, neuroblastoma, leukemia, squamous cell carcinoma of the esophagus, CRC and thyroid cancer
(55–59)
Kurayoshi et al, 2006 Kurayoshi et al, 2006; Huang et al, 2005 Bo et al, 2013
Wnt5a
GOF
Prostate, gastric, pancreatic, ovarian and non-small-cell lung cancer
(59–62)
Navarrete-Meneses et al, 2017 Stewart et al, 2014
Wnt5b
GOF
Acute lymphoblastic leukemia
(63)
Kirikoshi et al, 2002
Wnt7a
LOF
Non-small cell lung cancer, CRC, pancreatic and gastric cancer
(64,65)
Huang et al, 2015; Kirikoshi et al, 2002 Vesel et al, 2017
Wnt7b
GOF
Breast cancer, adenocarcinoma and embryonal tumor
(43,65,66)
Li et al, 2019; Li et al, 2017; Hsu et al, 2012 Kirikoshi et al, 2001; Dong et al, 2017
Wnt10a
GOF
CRC, ovarian cancer, renal cell carcinoma, esophageal and gastric cancer and papillary thyroid carcinoma
(67–71)
Wend et al, 2013; Chen et al, 2013 Saitoh et al, 2001
Wnt10b
GOF
Triple-negative breast and endometrial cancer and gastric carcinogenesis
ncRNAs regulate Wnt/β-catenin signaling in colorectal cancer drug resistance.
Author, year
ncRNAs
Dysregulation
Target
Mechanism
Function on drug resistance
(Refs.)
Shi et al, 2019
miR-148a
Upregulated
Wnt10b
Inhibiting the Wnt/β-catenin signaling
Increasing cisplatin-sensitivity
(26)
Chen et al, 2019
miR-103/107
Upregulated
Axin2
Prolonging the duration of Wnt/β-catenin signaling
Increasing drug resistance
(131)
Liang et al, 2017
miR-224
Upregulated
GSK-3β
Inhibiting Wnt/β-catenin signaling activity and survivin expression
Decreasing MDR
(134)
Zhou et al, 2017
miR-506
Upregulated
β-catenin
Inhibiting the expression of MDR1/P-gp of Wnt/β-catenin signaling
Enhancing L-OHP sensitivity
(132)
Kwak et al, 2018
miR-552
Upregulated
P53 gene
Activated by Wnt/c-Myc axis to inhibit p53
Increasing drug resistance
(142)
Wang et al, 2018
miR-372/373
Upregulated
/
Activated by Wnt/β-catenin signaling to enrich CD26/CD24
Increasing drug resistance
(144)
Han et al, 2017
CRNDE
Upregulated
miR-181a-5p
Activating β-catenin and TCF4
Causing resistance to 5-FU and L-OHP
(145)
Xiao et al, 2018
HOTAIR
Upregulated
miR-203a-3p
Activating Wnt/β-catenin signaling
Promoting cell resistance
(146)
Wu et al, 2017
H19
Upregulated
/
Activating Wnt/β-catenin signaling to activate proliferation
Promoting resistance to the MTX
(147)
Ma et al, 2016
CCAL
Upregulated
AP-2α
Activating Wnt/β-catenin signaling to upregulate MDR1P-gp expression
Inducing MDR
(149)
/indicates that detailed information was not provided in the reference. miR, microRNA; ncRNAs, non-coding RNAs; Axin2, Axis inhibition protein2; GSK3β, glycogen synthetase 3β; MDR, multidrug resistance; 5-FU, 5-fluorouracil; MTX, methotrexate; CRNDE, long non-coding RNA CRNDE; TCF4, T cell factor4; H19, long non-coding RNA H19; HOTAIR, long non-coding RNA HOTAIR; CCAL, long non-coding RNA CCAL; AP-2α, activating enhancer-binding protein 2 α; MDR1P-gp, MDR1P-glycoprotein.